WVP
VKTX icon

Worth Venture Partners’s Viking Therapeutics VKTX Stock Holding History

Worth Venture Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,600
Closed -$33.8K – 73
2024
Q2 		$33.8K Buy
+11,600
New +$760K 0.25% 49

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Worth Venture Partners's VKTX Position: Q3 2024 in Review

Worth Venture Partners sold out of Viking Therapeutics (VKTX) in Q3 2024, closing a stake of 10,100 shares — an estimated $593K sold.

Worth Venture Partners first reported a position in VKTX in Q2 2024 and held it in 1 quarter. The position peaked at $535K in Q2 2024. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • Worth Venture Partners reported no remaining Viking Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Worth Venture Partners sold 10,100 Viking Therapeutics shares in Q3 2024, an estimated $593K.
  • Worth Venture Partners first reported a position in Viking Therapeutics in Q2 2024 and held it in 1 quarter.
  • Worth Venture Partners's Viking Therapeutics position peaked at $535K in Q2 2024.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Worth Venture Partners's 13F filing for Q3 2024, filed 14 Nov 2024.